Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213694 | 1.00 | EDNRA (0.34) | EDNRAEDNRBMAPTALOX15HTT | |
| SCHEMBL15104959 | 0.79 | EDNRA (0.36) | EDNRAEDNRBMAPTALOX15HTT | |
| SCHEMBL2404932 | 0.79 | EDNRA (0.40) | EDNRAEDNRBMAPTALOX15HTT | |
| SCHEMBL27925789 | 0.78 | EDNRA (0.35) | EDNRAEDNRBMAPTALOX15HTT | |
| SCHEMBL2400874 | 0.72 | EDNRA (0.37) | EDNRAEDNRBALOX15LMNAALDH1A1 | |
| SCHEMBL30522434 | 0.72 | EDNRA (0.37) | EDNRAEDNRBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL27970746 | 0.72 | EDNRA (0.38) | EDNRAEDNRBMAPTALOX15LMNA | |
| SCHEMBL8797292 | 0.70 | HTR2A (0.43) | EDNRAEDNRBLMNAALDH1A1CYP2D6 | |
| SCHEMBL129881 | 0.68 | CYP2D6 (0.44) | EDNRAEDNRBMAPTALOX15HTT | |
| SCHEMBL31379445 | 0.68 | CYP2D6 (0.44) | EDNRAEDNRBMAPTALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| US-7217705-B2 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2004-10-21 | — | — | US | disclosed |
| US-5676831-A | ANXIOLYTIC AGENTS, ANTICONVULSANTS | RHONE-POULEC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | EDNRA 222/4885EDNRB 294/4885MAPT 2288/4885 |
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | CNR1, CNR2, GPR18 | EDNRA 211/4885EDNRB 258/4885MAPT 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.